BMO Capital analyst John Kim downgrades UDR (NYSE:UDR) from Outperform to Market Perform and announces $54 price target.
Aquestive Therapeutics Sees FY23 Revenue $37M-$41M Vs $37.83M Est.
2023 Outlook
Aquestive is providing its full year 2023 financial outlook.
The Company expects:
Guidance
Total revenue (in millions)
$37 to $41
Non-GAAP adjusted EBITDA
